Document is current

Article History

Accepted: 4 June 2025

First Online: 26 June 2025

Declarations

:

: This study was supported by Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

: Xiaohua Hou , Tao Bai, Zhiyue Xu, Yanbo Zhen, Aijun Liao, Bangmao Wang, Rong Zhao, Yin Zhu, Ning Dai, Side Liu,Hong Zhao, Xi Chen, Kunming Huang, Min Xu, Weizhen Zhou, Baohong Xu, Bin Ye, Duowu Zou, Heng Zhang,Ruihua Shi, Juan Zhang, Yaowei Ai, Xiangming Fang, Lin Lin, Xiaolan Zhang, Ling Zhang, Junping Wang, YuepingJiang, Jun Cui, Mingxin Zhang, Xiangwu Ding, Zhongyin Zhou, Peng Yan, Xiaoqing Li, Bo Jiang, Youli Liu, Yingcai Ma,Shaoqi Yang, Xiaoyan Wang, Yongdong Wu, Jianjun Wu and Huixin Chen received grants as study investigators from Shandong Luoxin Pharmaceutical Group Stock Co., Ltd .

: This clinical trial adhered to the Declaration of Helsinki and good clinical practice guidelines, with approval from the ethics committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2021-0035). The study was registered on ClinicalTrials.gov (NCT0515132).

: Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: The de-identified datasets generated and analyzed during the current study are not publicly available but may be available at a reasonable request upon approval by the corresponding author and an independent review committee.

: Not applicable.

: XH conceived and designed the study. All the authors contributed to data collection. TB and ZX analyzed and interpreted the data and developed the initial draft. All authors critically revised the manuscript and approved of the final version.